Pharmacy & Therapeutics- July 2008 - (Page 415) CONTINUING EDUCATION CREDIT triptan. Headache 2003;43(9):994–999. 157. Tepper SJ, Rapoport AM, Sheftell FD. Mechanisms of action of the 5-HT1B/1D receptor agonists. Arch Neurol 2002;59(7):1084–1088. 158. Durham P, Russo A. New insights into the molecular actions of serotonergic antimigraine drugs. Pharmacol Ther 2002;94(1–2):77–92. 159. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol 1990;99:202–206. 160. Jansen I, Edvinsson L, Mortensen A, et al. Sumatriptan is a potent vasoconstrictor of human dural arteries via a 5-HT1 like receptor. Cephalalgia 1992;12:202–205. 161. Humphrey A, Goadsby PJ. The mode of action of sumatriptan is vascular? A debate. Cephalalgia 1994;14:401–410. 162. Fullerton T, Gengo FM. Sumatriptan: A selective 5-hydroxytriptamine receptor agonist for the acute treatment of migraine. Ann Pharmacother 1992;26:800–807. 163. Ryan RE. Patient treatment preferences and the 5-HT1B/1D agonists. Arch Intern Med 2001;161:2545–2553. 164. Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: A comparative review of pharmacology, pharmacokinetics, and efficacy. Drugs 2000;50:1259–1287. 165. Gobel H, Winter P, Boswell D, et al. Comparison of naratriptan and sumatriptan in recurrence-prone migraine patients. Clin Ther 2000; 22:981–989. 166. Dixon R, French S, Kemp J, et al. Effect of hepatic impairment on the pharmacokinetics of zolmitriptan. J Clin Pharmacol 1998;38: 694–701. 167. Yu DK. The contribution of P-glycoprotein to pharmacokinetic drug–drug interactions. J Clin Pharmacol 1999;39:1203–1211. 168. Pascual J, Munoz P. Correlation between lipophilicity and triptan outcomes. Headache 2005;45(1):3–6. 169. Ferrari MD, Roon KI Lipton RB, et al. Oral triptans in acute migraine treatment: A meta-analysis of 53 trials. Lancet 2001;358:1668–1675. 170. Dahlof CG, Pascual J, Dodick DW, et al. Efficacy, speed of action, and tolerability of almotriptan in the acute treatment of migraine: Pooled individual patient data from four randomized, double-blind, placebo-controlled clinical trials. Cephalalgia 2006;26(4):400–408. 171. Winner P, Linder SL, Lipton RB, et al. Eletriptan for the acute treatment of migraine in adolescents: Results of a double-blind, placebocontrolled trial. Headache 2007;47(4):511–518. 172. Poolsup N, Leelasangaluk V, Jittangtrong J, et al. Efficacy and tolerability of frovatriptan in acute migraine treatment: Systemic review of randomized controlled trials. J Clin Pharm Ther 2005;30(6): 521–532. 173. Ahonen K, Hamalainen ML, Eerola M, et al. A randomized trial of rizatriptan in migraine attacks in children. Neurology 2006;67(7): 1135–1140. 174. Tepper SJ, Cady R, Dodick D, et al. Oral sumatriptan for the acute treatment of probable migraine: First randomized, controlled trial. Headache 2006;46(1):115–124. 175. Goadsby PJ, Massiou H, Pascual J, et al. Almotriptan and zolmitriptan in the acute treatment of migraine. Acta Neurol Scand 2007; 115(1):34–40. 176. Mandema JW, Cox E, Alderman J, et al. Therapeutic benefit of eletriptan compared to sumatriptan for the acute relief of migraine pain. Cephalagia 2005;25(9):715–725. 177. Diener HC, Gendolla A, Gebert I, et al. Almotriptan in migraine patients who respond poorly to oral sumatriptan: A double-blind, randomized trial. Headache 2005;45(7):874–882. 178. Rapoport AM, Tepper SJ, Sheftell FD, et al. Which triptan for which patient? Neurol Sci 2006;27:S123–S129. 179. Goldstein J, Tiseo PT, Albert KS, et al. Eletriptan in migraine patients reporting unsatisfactory response to rizatriptan. Headache 2006; 46(7):1142–1150. 180. Diener HC. Efficacy of almotriptan 12.5 mg in achieving migrainerelated composite endpoints: A double-blind, randomized, placebocontrolled study in patients with a previous poor response to sumatriptan 50 mg. Curr Med Res Opin 2005;21(10):1603–1610. 181. Dahlof CG. Infrequent or non-response to oral sumatriptan does not predict response to other triptans: Review of four trials. Cephalalgia 2006;26(2):98–106. 182. Lainez MJ, Evers S, Kinge E, et al. Preference for rizatriptan 10-mg wafer vs. eletriptan 40-mg tablet for acute treatment of migraine. Cephalalgia 2006;26(3):246–256. 183. Diez FI, Straube A, Zanchin G. Patient preference in migraine therapy: A randomized, open-label, crossover clinical trial of acute treatment of migraine with oral almotriptan and rizatriptan. J Neurol 2007;254(2):242–249. 184. Evers S, Rahmann A, Kraemer C, et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology 2006;67(3):497–499. 185. Friedman BW, Corbo J, Lipton RB, et al. A trial of metoclopramide vs. sumatriptan for the emergency depar tment treatment of migraines. Neurology 2005;64(3):463–468. 186. Friedman BW, Hochberg M, Esses D, et al. A clinical trial of trimethobenzamide/diphenhydramine versus sumatriptan for acute migraines. Headache 2006;46(6):934–941. 187. Martin VT, Loder E, Taylor K, et al. Eletriptan treatment of migraine in patients switching from barbiturate-containing analgesics: Results from a multiple attack study. Cephalalgia 2005;25(9):726–734. 188. Pascual J, Garcia-Monco C, Roig C, et al. Rizatriptan 10-mg wafer versus usual non-triptan therapy for migraine: Analysis of return to function and patient preference. Headache 2005;45(9):1140–1150. 189. Brandes JL, Kudrow D, Stark SR, et al. Sumatriptan-naproxen for acute treatment of migraine: A randomized trial. JAMA 2007; 297(13):1443–1454. 190. Dahlof C. Sumatriptan nasal spray in the acute treatment of migraine: A review of clinical studies. Cephalalgia 1999;19:769–778. 191. Ensink FB. Subcutaneous sumatriptan in the acute treatment of migraine. J Neurol 1991;238:S66–S69. 192. Jamieson DG. The safety of triptans in the treatment of patients with migraine. Am J Med 2002;112:135–140. 193. Dodick D, Lipton RB, Martin V, et al. Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT Agonists) in the Acute Treatment of Migraine. Headache 2004;44(5):414–425. 194. Maassen VanDen Brink A, Reekers M, Bax WA, et al. Coronary sideeffect potential of current and prospective antimigraine drugs. Circulation 1998;98:25–30. 195. Laine K, Raasakka T, Mantynen J, et al. Fatal cardiac arrhythmia after oral sumatriptan. Headache 1999;39:511–512. 196. Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, et al. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006;67(7):1128–1134. 197. Pacheco-Coronado R, McMullan PW, Galbut BH, et al. Myocardial infarction after taking zolmitriptan. Yale J Biol Med 2005;78(3): 147–150. 198. Arora A, Arora S. Spontaneous splenic infarction associated with sumatriptan use. J Headache Pain 2006;7(4):214–216. 199. Fulton JA, Kahn J, Nelson LS, et al. Renal infarction during the use of rizatriptan and zolmitriptan: Two case reports. Clin Toxicol 2006; 44(2):177–180. 200. Repaka A, Wenger J, Sitaraman SV. A case of sumatriptan-induced intestinal ischemia. J Gastroenterol 2006;41(2):177–178. 201. Tepper SJ. Safety and rational use of the triptans. Med Clin North Am 2001:85(4):959–970. 202. Martin VT, Goldstein JA. Evaluating the safety and tolerability profile of acute treatments for migraine. Am J Med 2005;228(Suppl 1):36S–44S. 203. Hilaire ML, Cross LB, Eichner SF. Treatment of migraine headaches with sumatriptan in pregnancy. Ann Pharmacother 2004;38(10): 1726–1730. 204. Gardner DM, Lynd LD. Sumatriptan contraindications and serotonin syndrome. Ann Pharmacother 1998;32:33–38. 205. Shapiro RE, Tepper SJ, et al. The serotonin syndrome, triptans and the potential for drug–drug interactions. Headache 2007;47:266–269. 206. Wooltorton E. Triptan migraine treatment and antidepressants: Risk of serotonin syndrome. Can Med Assoc J 2006;175(8):874. 207. Eadie M. Clinically significant drug interactions with agents specific for migraine attacks. CNS Drugs 2001;15(2):105–118. 208. Goldberg MR, Lowry RC, Musson DG, et al. Lack of pharmacokinetic and pharmacodynamic interaction between rizatriptan and paroxetine. J Clin Pharmacol 1999;39:192–199. 209. Michalets EL. Update: Clinically significant cytochrome P-450 drug interactions. Pharmacotherapy 1998;18(1):84–112. 210. Goldberg MR, Sciberras D, De Smet M, et al. Influence of betaadrenoceptor antagonists on the pharmacokinetics of rizatriptan, a Vol. 33 No. 7 • July 2008 • P&T® 415
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.